Personalis Inc (STU:04X)
€ 1.296 0.109 (9.18%) Market Cap: 64.30 Mil Enterprise Value: 19.80 Mil PE Ratio: 0 PB Ratio: 0.62 GF Score: 64/100

Personalis Inc at UBS Global Healthcare Conference Transcript

May 24, 2022 / 07:30PM GMT
Release Date Price: €3.81 (-8.17%)
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate

I'm John Sourbeer, I'm one of the analysts covering Life Sciences at UBS. For our next fireside chat, we have Personalis, and with us today is Aaron Tachibana, who is the CFO. Hi, Aaron.

Aaron L. Tachibana
Personalis, Inc. - Senior VP & CFO

Thank you, John. Thanks for having us.

John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate

So just to get started here, maybe for some that are new to Personalis in the room. Maybe just could you provide us a quick overview on the company before we start to get into the Q&A and just where the company is today?

Aaron L. Tachibana
Personalis, Inc. - Senior VP & CFO

Sure, happy to. So Personalis is a leader of advanced cancer genomics and we basically help pharmaceutical companies with drug development for precision cancer therapies. In addition, we're going to be taking our business into the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot